Pomalidomide NEW
| Price | $52 | $78 | $101 |
| Package | 10mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-19 |
Product Details
| Product Name: Pomalidomide | CAS No.: 19171-19-8 |
| Purity: 98.8% | Supply Ability: 10g |
| Release date: 2025/05/19 |
Product Introduction
Bioactivity
| Name | Pomalidomide |
| Description | Pomalidomide (CC-4047) is an anti-angiogenic and immunomodulatory agent. Pomalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN) and is commonly used in the synthesis of PROTAC products. |
| Cell Research | In vitro effects of either CC-5013 or CC-4047 as single agent or in combination with rituximab were evaluated by flow cytometric analysis. Lymphoma cell lines (1 × 10^6 cells) were exposed to either CC-5013 (5 μg/mL), CC-4047 (5 μg/mL), or vehicle control (DMRIE-C, 0.01%) alone or in combination with rituximab at a final concentration of 10 μg/mL. Following a period of incubation of 24 or 48 hours, apoptosis was assessed by staining-treated cells with FITC-labeled Annexin V and propidium iodine. All samples were analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells were scored as apoptotic if they were Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively) [2]. |
| Kinase Assay | TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that IC50 is calculated by nonlinear regression analysis [1]. |
| Animal Research | These studies were carried out using a disseminated lymphoma-bearing SCID mouse xenograft model. Raji cells were harvested from confluent cultures and only suspensions with >90% viable cells were used for animal inoculation. Subsequently, on day 0, SCID mice received 1 ×10^6 Raji cells via i.v. Untreated SCID mice inoculated by i.v. injection develop symptomatic central nervous system, pulmonary, and liver metastasis that result in death from massive tumor burden and central nervous system involvement after 17 to 21 days after inoculation. A second lymphoma mouse model was used to address the significance of NK cell expansion in the biological interactions observed between rituximab and IMiDs. The second mouse lymphoma xenograft consisted of SCID mice depleted of NK cells bearing Raji cells implanted via tail vein injection as described above [2]. |
| In vitro | METHODS: Multiple myeloma cells RPMI8226 and OPM2 were treated with Pomalidomide (0.01-50 μM) for 48 h. Cell viability was measured by MTT assay. RESULTS: Pomalidomide significantly decreased the cell viability of RPMI8226 and OPM2 cells at 48 h with IC50 values of 8 μM and 10 μM, respectively.[1] METHODS: Multiple myeloma cells H929, U266 and MM.1s were treated with Pomalidomide (0.05-1 μM) and ACY-241 (3 μM) for 4 days and apoptosis was detected by Flow cytometry. RESULTS: Apoptosis was significantly increased when the two drugs were combined relative to either single drug. [2] |
| In vivo | METHODS: To assess the potential value in cerebral ischemia, Pomalidomide (50 mg/kg, 1% carboxy methyl cellulose) was administered intraperitoneally once daily for 21 days to transgenic mice chronically overexpressing the TNF-α surface-active protein (SP)-C promoter (SP-C/TNF-α mice). RESULTS: Pomalidomide significantly reduced serum TNF-α and IL-5 levels. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 50 mg/mL (182.99 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5.4 mg/mL (19.76 mM), Suspension. |
| Keywords | TNF-α | Pomalidomide | MolecularGlues | Molecular Glues | Ligands for E3 Ligase | LigandforE3Ligase | Ligand for E3 Ligase | Inhibitor | inhibit | E3 ligase-recruiting Moiety | CC4047 | CC 4047 | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $0.00/1kg |
VIP1Y
|
Wuhan Circle Star Chem-medical Technology Co.,Ltd
|
2024-12-25 | |
| $10.00/1KG |
VIP7Y
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-12-04 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-09-25 | |
| $19.00/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-19 | |
| $0.00/1kg |
VIP2Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-05-13 | |
| $0.00/25kg |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-09-07 | ||
| $0.00/1g |
VIP3Y
|
shandong perfect biotechnology co.ltd
|
2023-08-14 | |
| $30.00/1kg |
Henan Bao Enluo International TradeCo.，LTD
|
2023-08-11 | ||
| $180.00/1KG |
Weijer International Trade (Hebei) Co., Ltd
|
2023-03-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY